Assessment of Pentoxifylline effects on liver steatosis utilizing Dixon-based MRI technique; randomized controlled study.

Sahar H.Elhini, Asmaa A Elsayed, A. Elberry, Nadia F. El Ameen, Ahmed Abdelfadil Saedii, M. Ibrahim, Nadia Ismail, Haitham Saeed, H. Rabea
{"title":"Assessment of Pentoxifylline effects on liver steatosis utilizing Dixon-based MRI technique; randomized controlled study.","authors":"Sahar H.Elhini, Asmaa A Elsayed, A. Elberry, Nadia F. El Ameen, Ahmed Abdelfadil Saedii, M. Ibrahim, Nadia Ismail, Haitham Saeed, H. Rabea","doi":"10.21608/bfsa.2023.177573.1591","DOIUrl":null,"url":null,"abstract":"Background: Pentoxifylline (PTX) has been proven to reduce hepatic steatosis in animal models; however, data regarding its safety and efficacy in type-2 diabetics (T2D) with nonalcoholic fatty liver disease (NAFLD) are rare. Aim: Determine the effects of PTX in reducing liver fat content (LFC; %) in T2D patients with NAFLD in various disease states. Methods: 187 T2D subjects with NAFLD were randomized to receive either Pentoxifylline 800 mg (PTX group) or standard T2D care only (control group) for 24 weeks. The primary outcomes included changes in LFC (%) as measured by magnetic resonance imaging-derived proton density fat-fraction technique (MRI-PDFF) and the calculation of a fibrosis score (NFS). Results: PTX significantly reduced LFC (%) more than the control group (-8.18 vs. -1.87; P< 0.0001). Only the PTX group significantly reduced the NFS score (-1.16; P<0.0001). The PTX group showed significant LFC changes in liver segments II (-9.77; P< 0.0001), IVb (-9.51; P< 0.0001), and VI (-9.13; P< 0.0001); however, the control group achieved significant LFC changes in liver segments III (-2.57; P= 0.02) and VI (-2.22; P= 0.04). In subgroup analysis, PTX showed comparable efficacy in decreasing LFC in different fibrosis scores, gender, and BMI categories. However, Patients with severe steatosis grade (LFC>22.1%) (-10.55%; P=0.001) and HbA1c levels > 7.5% (-8.75%; P= 0.015) achieved significantly higher LFC reductions than other steatosis grades and HbA1c categories. Conclusion: PTX presented a similar efficacy profile in reducing LFC in different fibrosis scores, genders, and BMI categories, while patients with severe steatosis grade and HbA1c > 7.5% achieved higher LFC reductions.","PeriodicalId":345040,"journal":{"name":"Bulletin of Pharmaceutical Sciences. Assiut","volume":"10 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2023-01-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Bulletin of Pharmaceutical Sciences. Assiut","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.21608/bfsa.2023.177573.1591","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Pentoxifylline (PTX) has been proven to reduce hepatic steatosis in animal models; however, data regarding its safety and efficacy in type-2 diabetics (T2D) with nonalcoholic fatty liver disease (NAFLD) are rare. Aim: Determine the effects of PTX in reducing liver fat content (LFC; %) in T2D patients with NAFLD in various disease states. Methods: 187 T2D subjects with NAFLD were randomized to receive either Pentoxifylline 800 mg (PTX group) or standard T2D care only (control group) for 24 weeks. The primary outcomes included changes in LFC (%) as measured by magnetic resonance imaging-derived proton density fat-fraction technique (MRI-PDFF) and the calculation of a fibrosis score (NFS). Results: PTX significantly reduced LFC (%) more than the control group (-8.18 vs. -1.87; P< 0.0001). Only the PTX group significantly reduced the NFS score (-1.16; P<0.0001). The PTX group showed significant LFC changes in liver segments II (-9.77; P< 0.0001), IVb (-9.51; P< 0.0001), and VI (-9.13; P< 0.0001); however, the control group achieved significant LFC changes in liver segments III (-2.57; P= 0.02) and VI (-2.22; P= 0.04). In subgroup analysis, PTX showed comparable efficacy in decreasing LFC in different fibrosis scores, gender, and BMI categories. However, Patients with severe steatosis grade (LFC>22.1%) (-10.55%; P=0.001) and HbA1c levels > 7.5% (-8.75%; P= 0.015) achieved significantly higher LFC reductions than other steatosis grades and HbA1c categories. Conclusion: PTX presented a similar efficacy profile in reducing LFC in different fibrosis scores, genders, and BMI categories, while patients with severe steatosis grade and HbA1c > 7.5% achieved higher LFC reductions.
己酮茶碱对肝脂肪变性的MRI评价随机对照研究。
背景:己酮茶碱(PTX)在动物模型中已被证明可以减少肝脏脂肪变性;然而,关于其在2型糖尿病(T2D)合并非酒精性脂肪性肝病(NAFLD)中的安全性和有效性的数据很少。目的:探讨紫癜性胆碱对降低肝脏脂肪含量的影响;%)在不同疾病状态的t2dm NAFLD患者中。方法:187例合并NAFLD的T2D患者随机分为两组,一组接受自己可可碱800 mg (PTX组),另一组仅接受标准T2D治疗(对照组),疗程24周。主要结果包括通过磁共振成像衍生质子密度脂肪分数技术(MRI-PDFF)测量的LFC(%)的变化和纤维化评分(NFS)的计算。结果:PTX显著降低LFC(%)高于对照组(-8.18 vs -1.87;P < 0.0001)。只有PTX组显著降低了NFS评分(-1.16;P22.1%) (-10.55%;P=0.001), HbA1c水平> 7.5% (-8.75%;P= 0.015)的LFC降低率明显高于其他脂肪变性分级和HbA1c类别。结论:PTX在降低不同纤维化评分、性别和BMI类别的LFC方面具有相似的疗效,而重度脂肪变性和HbA1c > 7.5%的患者LFC降低率更高。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信